Chromosomal translocations of the MLL H3K4 histone methyltransferase gene on chromosome 11q23 are associated with unique subsets of both acute lymphoblastic (ALL) and acute myeloid leukemias (AML). 1 The MLL gene encodes for a large protein of 3969 amino acids and has a role in chromatin-mediated transcriptional regulation. 2 Translocations of chromosome 11q23 usually result in a chimeric fusion gene retaining the N-terminal part of the MLL gene fused to a C-terminal partner gene, which acts to transform normal hematopoietic cells. 3 In adults, MLL rearrangements are detected in 3% of de novo AML and in 10% of therapy-related AML (t-AML) cases, and are associated with an aggressive course of disease and poor prognosis. 3 Recently, highthroughput sequencing studies had shown that in addition to disease defining mutations almost all myeloid malignancies accumulate a large number of cooperating gene mutations. 4 Therefore, we here investigated the occurrence and prognostic impact of somatic mutations in adult AML cases harboring MLL rearrangements.
Bone marrow and peripheral blood specimens of 4686 de novo AML and 313 t-AML cases, sent for diagnosis to the MLL Munich Leukemia Laboratory between 08/2005 and 11/2012, were included. Within this unselected cohort translocations involving chromosome 11q23 were identified by chromosome banding analysis in 134 de novo and 53 t-AML cases. All MLL rearrangements were verified by fluorescence in situ hybridization and/or reverse transcriptase PCR (RT-PCR), resulting in a frequency of 2.8% and 14.5%, respectively. On the basis of the availability of specimens for further analyses, a total cohort of 118 adult AML cases was selected (85 de novo, 33 t-AML) for subsequent molecular studies. The cohort was composed of 72 female and 46 male patients, and the median age was 53.3 years (range: 19.3-83.5 years). Additional clinical data and information on the fusion partner genes are depicted in Table 1 . Further, survival data were available in 94 cases (median overall survival (OS) was 16.2 months). OS and event-free survival (EFS) did not differ between de novo and t-AML cases (median OS: 16.7 vs 12.1 months, P ¼ 0.461; median EFS: 9.2 vs 9.8 months, P ¼ 0.948).
All cases were analyzed by chromosome banding analysis. Further, the samples were screened for mutations in the candidate genes ASXL1, BRAF, CBL, CEBPA, FLT3-ITD, FLT3-TKD, IDH1, IDH2, KIT, KRAS, NPM1, NRAS, PTPN11, RUNX1, TP53 and WT1 using amplicon deep-sequencing (454 Roche Life Sciences, Branford, CT, USA), direct Sanger sequencing or melting curve analysis as previously described. 5, 6 EVI1 gene expression was measured using quantitative RT-PCR. 7 First, the characteristics of specific MLL fusion partners were analyzed. In these investigations only cases with the following fusion genes MLL-MLLT3 (AF9), n ¼ 48; MLL-ELL, n ¼ 18; MLL-MLLT4 (AF6), n ¼ 17; and MLL-MLLT10 (AF10), n ¼ 9 were included. Twenty-six patients with other MLL partner genes were excluded from this analysis because of low case numbers. The MLL-MLLT4 fusion was negatively associated with t-AML (0/17 vs 33/101, P ¼ 0.003). In contrast, patients with t-AML frequently showed a MLL-ELL fusion (9/18 vs 24/100, P ¼ 0.042). Further, MLL-MLLT10 was associated with lower age (43.8±9.5 vs 54.5±17.0, P ¼ 0.011) and MLL-MLLT3 with higher white blood cell (WBC) count (81.8 ± 83.2 vs 48.5 ± 51.2 Â 10 9 /l, P ¼ 0.032). In contrast to published data, no association between OS or EFS and the Letters to the Editor distinct fusion partners was detected, neither for the t(9;11) (p22;q23)/MLL-MLLT3 fusion. 8, 9 Further, 50/118 (42.4%) MLL-rearranged cases showed at least one additional chromosomal alteration (median: 2 aberrations, range: 1-18). Thirty-one (62.0%) cases showed 1-2 and 19 (38.0%) cases X3 aberrations. The most common concomitant cytogenetic alterations were þ 8 (n ¼ 19/50, 38.0%) and þ 21 (n ¼ 9/50, 18.0%). For none of the cytogenetic aberrations associations with clinical parameters or with the OS and EFS were observed. This was also true for the absolute number of cytogenetic aberrations.
At least one concomitant molecular alteration was identified in 68/118 (57.6%) cases ( Figure 1a) . The most commonly affected pathway was the RAS signalling pathway, that is, 59/118 (50.0%) MLL-translocated AML cases harbored mutations in NRAS: 26/118 (22.0%), KRAS: 24/118 (20.3%), PTPN11: 4/118 (3.4%) and BRAF: 3/ 118 (2.5%) or alterations in the RAS regulating FLT3 gene (FLT3-ITD: 5/117 (4.3%) and FLT3-TKD: 10/113 (8.8%)).
The observed RAS pathway alterations tended to be mutually exclusive ( Figure 1a ) and only five cases harbored both NRAS and KRAS mutations in parallel. In 3/5 patients, the difference in the mutation loads as assessed by deep-sequencing read counts suggested the presence of distinct subclones within the AML blast population, whereas two cases showed mutations with similar clone size. Further, we were interested in the stability of such RAS pathway mutations during the course of the disease. Thus, four paired samples of cases with mutations present at diagnosis in NRAS (n ¼ 2), KRAS (n ¼ 1) and BRAF (n ¼ 1) were also sequenced at the stage of clinical relapse. Here, we observed that in 3/4 cases the subclones with RAS pathway mutations detected at diagnosis were not detectable at relapse. This was true for NRAS and BRAF mutations. In contrast, in the fourth case harboring a KRAS mutation, the KRAS mutation showed a pattern coincident with the MLL fusion gene. Both the t(6;11)(q27;q23) and p.Gly12Asp mutant disappeared under treatment and were both detectable again at relapse stage. This data supports the hypothesis that RAS mutations are present in subclones in AML with MLL rearrangements, as suggested by others. 10 Analogous to this study, Metzeler et al. 11 identified mutations in KRAS (n ¼ 14, 42.4%), NRAS (n ¼ 6, 18.2%) and FLT3 (n ¼ 5, 15.2%) in 33 adult AML patients with MLL-MLLT3 fusion. A similar finding was described for ALL by Andersson et al. 12 observing mutated KRAS (n ¼ 4, 18.2%), or NRAS (n ¼ 2, 9.1%) or mutations in NF1 and PTPN11 (one case each) in 22 infant cases with 11q23 translocations. Further, Driessen et al. 10 investigated a large cohort of 109 infant MLL-rearranged leukemia for mutations in NRAS, KRAS and BRAF. They observed an overall mutation frequency of 13.8% (15/109), with particular NRAS mutations in 6.4% (7/109) and KRAS mutations in 7.2% (8/109) of cases. No mutation was detected in BRAF. 10 In addition, high mutation frequency of RAS pathway genes or RAS pathway regulating genes was also described in 92 and 84% of patients with CBFB- MYH11 rearrangement 13, 14 and in patients with inv(3)(q21q26)/ t(3;3)(q21;q26) 15 as a second hit improving cellular survival and resulting in proliferation advantage.
As summarized in Figure 1a , additional molecular mutations were detected in the tumor suppressor gene TP53 (7/118; 5.9%), ASXL1 (5/110; 4.5%), RUNX1 (3/118; 2.5%) and WT1 (6/97; 6.2%). No mutation was detected in IDH1 (n ¼ 110), IDH2 (n ¼ 101), CBL (n ¼ 65), CEBPA (n ¼ 61), KIT (n ¼ 99) and NPM1 (n ¼ 118). Thus, we suspect these mutations to be mutually exclusive of MLL fusion genes. In summary, most cases showed only one mutation (n ¼ 47, 69.1%), whereas 17 cases (25.0%) showed mutations in two and four cases (5.6%) in three different genes.
Next, associations with somatic mutations and clinical parameters were studied, yet due to the relatively low mutation frequency in some genes and the low number of patients in subsets, the observed correlations will require further confirmation in independent adult MLL-rearranged patient cohorts. No difference in the mutation distribution between de novo and t-AML was detected (Table 2) . 51/85 (60.0%) Of de novo AML and 17/33 (51.5%) of t-AML showed at least one mutation (nonsignificant). Therefore, de novo and t-AML were combined for further analyses. Here, ASXL1 mutations were observed to be associated with lower hemoglobin level (8.4±0.8 vs 9.8±2.2 g/dl, P ¼ 0.007) and KRAS mutations with higher WBC count (89.2 ± 76.3 vs 54.8 ± 64.0 Â 10 9 /l, P ¼ 0.044). Similar to these results, also Driessen et al. 10 reported that RAS-mutated MLL-rearranged infants showed significant higher WBC counts at diagnosis (P ¼ 0.013).
Focusing on the different fusion partners, a strong association of MLL-ELL fusion with WT1 mutations (Po0.001) and FLT3-ITD (P ¼ 0.001) was detected, that is, 5/6 WT1 mutated cases and 4/5 cases with FLT3-ITD showed a MLL-ELL fusion. No associations within the various combinations of gene mutations and cytogenetic aberrations were observed. The distribution of mutated genes within the distinct categories of MLL rearrangements is depicted in Table 2 .
Furthermore, the prognostic impact of single gene mutations was investigated. Here, a significantly worse OS for TP53 mutated cases was observed: OS after 3 years for TP53 mutated cases (n ¼ 7) vs TP53 wild-type cases (n ¼ 87) was 0% vs 36.6%; median OS was 3.0 vs 16.9 months, P ¼ 0.029. Although components of the RAS signalling pathway were very commonly mutated in this AML subgroup, no impact on survival was observable. This is in contrast to infant MLL-rearranged ALL, where a shorter OS and EFS is described. 10 Further, the number of mutations showed no prognostic impact. Subsequently, the cohort was subdivided into younger (o60 years, n ¼ 68) and older (X60 years, n ¼ 50) patients. Of note, no correlation between mutation frequency and age was observed. However, a strong adverse impact of older age on OS and EFS was detected (median OS: 6.1 (n ¼ 37) vs 29.7 (n ¼ 57) months, OS after 3 years: 12.7% vs 45.2%, P ¼ 0.001; median EFS: 4.6 vs 10.1 months, EFS after 3 years: 10.1% vs 25.9%, P ¼ 0.007).
Previously, van Doorn-Khosrovani et al. 16 observed a high EVI1 expression in MLL translocated cases, probably because of the MLL control on the EVI1 transcription. Therefore, the EVI1 expression was investigated in this cohort using RT-PCR in 102/118 cases. The median %EVI1/ABL1 level was 83.0 (mean: 196.5, range: 0-1316.7), very similar to EVI1-rearranged cases analyzed in a previous series (median %EVI1/ABL1 92.8 (range: 29.8-146.1)). 15 The median %EVI1/ABL1 levels for the distinct MLL fusion genes are given in Table 1 and Figure 1a . Of note, MLL-MLLT4 showed significantly higher (465±282 vs 150±239, Po0.001) and MLL-MLLT10 lower (27 ± 48 vs 209 ± 275, Po0.001) %EVI1/ABL1 levels. In addition, 45 healthy controls were analyzed to determine the normal %EVI1/ ABL1 background level (median: 1.5, mean: 1.8 (range: 0-5.8)). This was significantly lower than in MLL-rearranged cases (Po0.001). According to the highest levels of the healthy controls, cases were divided into high (45.8, n ¼ 61) and low (o5.8, n ¼ 41) %EVI1/ ABL1 level for further correlation studies. Here, a positive association with female gender (43/61 vs 18/41, P ¼ 0.013), WT1 mutations (6/6 vs 43/80, P ¼ 0.035), MLL-MLLT4 (15/15 vs 46/87, Po0.001) and MLL-ELL (16/17 vs 45/85, P ¼ 0.001) was observed for a higher %EVI1/ABL1 level ( Table 2) . No impact on survival was detected.
In summary, in patients with MLL rearrangements a high number of secondary cytogenetic aberrations was detected (50/118, 42.4%). Regarding molecular genetics, somatic alterations were identified in 68/118 (57.6%) cases, predominantly affecting the RAS pathway or RAS regulating components (59/118, 50.0%). This may have implication on novel therapeutic options in this unfavorable AML subset, such as kinase inhibitors that act downstream of RAS targeting the RAF/MAPK or PI3K/AKT pathway or farnesyltransferase inhibitors preventing the post-translational modification of RAS inhibiting the correct localization in the plasma membrane. Survival rates for childhood acute lymphoblastic leukemia (ALL) have increased dramatically over the last four decades due to a combination of intensified treatment, improved supportive care and risk stratifications based on several parameters including genetic aberrations. However, 10-20% of patients treated according to modern protocols still relapse and 10% do not survive the disease. 1 Genetic lesions signaling high risk are rare and treatment failures occur across the whole spectrum of cytogenetic risk groups, while a substantial proportion of cases also lack characteristic rearrangements used for risk stratification. 2 Deletion of the IKZF1 locus, coding for the lymphoid transcription factor IKAROS, has recently emerged as a potential prognostic marker in B-cell precursor ALL (BCP ALL). 3 The vast majority of reported aberrations in IKZF1 are intragenic deletions, while sequencing of the IKZF1 gene has revealed a low frequency of point mutations. [4] [5] [6] [7] Heterozygous deletions of the entire IKZF1 locus or individual exons are predicted to result in haploinsufficiency, whereas deletion of a specific subset of exons (D4-7) results in a shorter, dominant-negative isoform, IK6. 8 Different isoforms of IKZF1, generated through alternative splicing, are expressed during normal B-cell development; 9 however, several studies have demonstrated that expression of the IK6 isoform is pathogenic and caused by deletion only. 10 Originally described as a characteristic of BCR-ABL1-positive ALL, 8 IKZF1 deletions were later suggested to predict high relapse risk and poor prognosis in all types of BCP ALL. 3 Moreover, these deletions have been associated with a gene expression profile resembling BCR-ABL1-positive ALL. 11 The aim of our study was to assess the frequency and prognostic impact of IKZF1 mutations in a consecutive cohort of children aged 1-18 diagnosed with BCP ALL from 2001 to 2011 at the Karolinska University Hospital in Stockholm and treated according to NOPHO (Nordic Society of Paediatric Haematology and Oncology) protocols. 1 During this period 148 children were diagnosed with BCP ALL, and DNA from bone marrow aspirates obtained at diagnosis was available from 120 of those cases. The median age of the cohort was 5 years, with a male to female ratio of 1.1. The median white blood cell count at diagnosis was 9.5 Â 10 9 /l. Routine cytogenetic analysis showed that the majority of cases belonged to low-risk genetic categories (72/120). A small number showed aberrations associated with intermediate risk (13/ 120) , and one patient was diagnosed with a high-risk, hypodiploid leukemia. In total, 34 out of 120 patients (28%) lacked riskstratifying aberrations at diagnosis. Only two BCR-ABL1-positive ALL cases were diagnosed in Stockholm during the period and no DNA was available from these patients. Two of the children had Down's syndrome. After risk group assignment according to NOPHO protocols, 40% were considered standard-risk, 44% intermediate-risk and 16% high-risk ALL.
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We used multiplex ligation-dependent probe amplification (MLPA) with the probe kits P335 and P202 from MRC-Holland (Amsterdam, The Netherlands) to investigate the presence of copy number alterations of IKZF1 in DNA from bone marrow samples taken at diagnosis. All 120 cases were analyzed with the probe kit P335 that contains one probe for each exon in the IKZF1 gene together with probes for several genes implicated in leukemia development: IKZF1, CDKN2A/B, PAX5, EBF1, BTG1, RB1, ETV6, CRLF2, SHOX, CSF2RA and IL3RA. Four samples failed MLPA due to poor sample quality. Cases that were found to harbor Accepted article preview online 29 March 2013; advance online publication, 19 April 2013
